A phase 3, multicenter, open-label, randomized, study of Gilteritinib versus Midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

Project: Research

Project Details

Project Description

Effective start/end date19/03/2118/03/26


  • clinical trial
  • phase 3 study
  • leukemia
  • treatment efficacy
  • treatment safety